{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:50:26Z","timestamp":1782391826725,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018736","name":"Kaken Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K18664"],"award-info":[{"award-number":["25K18664"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06707"],"award-info":[{"award-number":["22K06707"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eplepsyres.2025.107626","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T22:30:07Z","timestamp":1753137007000},"page":"107626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Principal component analysis of antiseizure medication-induced hostility\/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-0349","authenticated-orcid":false,"given":"Ryuichiro","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushirou","family":"Sogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Terajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Funada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2025.107626_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/pds.3454","article-title":"Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases","volume":"23","author":"Avillach","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The Epidemiology of Epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: An evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib5","first-page":"212","article-title":"Selection of differentially expressed genes in microarray data analysis","volume":"7","author":"Chen","year":"2007","journal-title":"Pharm. J."},{"issue":"10","key":"10.1016\/j.eplepsyres.2025.107626_bib6","first-page":"6503","article-title":"Prescription patterns of antiepileptic drugs for adult patients with newly diagnosed focal epilepsy from 2006 to 2017 in Japan","volume":"169","author":"Chen","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.0013-9580.2004.04014.x","article-title":"Status epilepticus and periictal imaging","volume":"45","author":"Cole","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/pds.3622","article-title":"Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database","volume":"23","author":"De Boissieu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","article-title":"Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases","volume":"4","author":"Dinkelacker","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ebcr.2014.04.001","article-title":"Homicide during postictal psychosis","volume":"2","author":"Eisenschenk","year":"2014","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib12","unstructured":"European Medicines Agency. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1-addendum_en.pdf\u3009 (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40801-022-00324-4","article-title":"Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Na\u00efve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database","volume":"9","author":"Hasegawa","year":"2022","journal-title":"Drugs Real. World Outcomes"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ph15010027","article-title":"Analysis of Factors Associated with Hiccups Using the FAERS Database","volume":"15","author":"Hosoya","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0165-0173(99)00023-5","article-title":"The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking","volume":"31","author":"Ikemoto","year":"1999","journal-title":"Brain Res Rev."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1248\/bpb.b21-00954","article-title":"Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database","volume":"45","author":"Kawada","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.neubiorev.2019.09.023","article-title":"Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence","volume":"107","author":"Krinzinger","year":"2019","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib19","unstructured":"Kyoto Encyclopedia of Genes and Genomes (KEGG). Entry D00426, \u3008https:\/\/www.kegg.jp\/entry\/D00426\u3009(Risperidone) (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib20","unstructured":"Kyoto Encyclopedia of Genes and Genomes (KEGG). Entry D00538, \u3008https:\/\/www.kegg.jp\/entry\/D00538\u3009(Zonisamide) (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib21","unstructured":"Kyoto Encyclopedia of Genes and Genomes (KEGG). Entry D00252, \u3008https:\/\/www.kegg.jp\/entry\/D00252\u3009(Carbamazepine) (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib22","unstructured":"Kyoto Encyclopedia of Genes and Genomes (KEGG). Entry D00354, \u3008https:\/\/www.kegg.jp\/entry\/D00354\u3009(Lamotrigine) (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib23","unstructured":"Kyoto Encyclopedia of Genes and Genomes (KEGG). Entry D00399, \u3008https:\/\/www.kegg.jp\/entry\/D00399\u3009 (Valproic acid) (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib25","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle is the protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib26","first-page":"51","article-title":"JADER from Pharmacovigilance Point of View","volume":"19","author":"Maeda","year":"2014","journal-title":"Jpn J. Pharmacoepidemiol"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: A more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib28","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). \u3008https:\/\/www.meddra.org\/26\u3009 (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00002826-200209000-00012","article-title":"Antiepileptic-antipsychotic drug interactions: A critical review of the evidence","volume":"25","author":"Mula","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/pharmaceutics12080762","article-title":"Subset Analysis for Screening Drug \u2013 Drug Interaction Signal Using Pharmacovigilance Database","volume":"12","author":"Noguchi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib31","unstructured":"Norwegian Institute of Public Health. ATC\/DDD Index. \u3008https:\/\/atcddd.fhi.no\/atc_ddd_index\/\u3009 (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Effect of competition bias in safety signal generation: Analysis of a research database of spontaneous reports in France","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s42494-021-00055-z","article-title":"The pharmacological treatment of epilepsy: recent advances and future perspectives","author":"Perucca","year":"2021","journal-title":"Acta Epileptol. 322"},{"key":"10.1016\/j.eplepsyres.2025.107626_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1254\/jphs.CPJ06010X","article-title":"A new frontier in epilepsy: Novel antiepileptogenic drugs","volume":"100","author":"Sasa","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib38","unstructured":"U.S Food and Drug Administration. FDA Adverse Event Reporting System (FAERS), \u3008https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard\u3009 (accessed: 18 March 2025)."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107626_bib40","unstructured":"World Health Organization. Epilepsy fact sheet, \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy#:\u223c:text=Epilepsy%20is%20a%20chronic%20noncommunicable,get%20the%20treatment%20they%20need\u3009 (accessed: 18 March 2025)."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:42:57Z","timestamp":1764016977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121125001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S0920121125001275"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107626","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Principal component analysis of antiseizure medication-induced hostility\/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107626"}}